Prospective, multi-site study of healthcare utilization after actionable monogenic findings from clinical sequencing
Copyright © 2023 American Society of Human Genetics. All rights reserved..
As large-scale genomic screening becomes increasingly prevalent, understanding the influence of actionable results on healthcare utilization is key to estimating the potential long-term clinical impact. The eMERGE network sequenced individuals for actionable genes in multiple genetic conditions and returned results to individuals, providers, and the electronic health record. Differences in recommended health services (laboratory, imaging, and procedural testing) delivered within 12 months of return were compared among individuals with pathogenic or likely pathogenic (P/LP) findings to matched individuals with negative findings before and after return of results. Of 16,218 adults, 477 unselected individuals were found to have a monogenic risk for arrhythmia (n = 95), breast cancer (n = 96), cardiomyopathy (n = 95), colorectal cancer (n = 105), or familial hypercholesterolemia (n = 86). Individuals with P/LP results more frequently received services after return (43.8%) compared to before return (25.6%) of results and compared to individuals with negative findings (24.9%; p < 0.0001). The annual cost of qualifying healthcare services increased from an average of $162 before return to $343 after return of results among the P/LP group (p < 0.0001); differences in the negative group were non-significant. The mean difference-in-differences was $149 (p < 0.0001), which describes the increased cost within the P/LP group corrected for cost changes in the negative group. When stratified by individual conditions, significant cost differences were observed for arrhythmia, breast cancer, and cardiomyopathy. In conclusion, less than half of individuals received billed health services after monogenic return, which modestly increased healthcare costs for payors in the year following return.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:110 |
|---|---|
| Enthalten in: |
American journal of human genetics - 110(2023), 11 vom: 02. Nov., Seite 1950-1958 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 06.11.2023 Date Revised 03.05.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ajhg.2023.10.006 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363760709 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363760709 | ||
| 003 | DE-627 | ||
| 005 | 20240503232149.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ajhg.2023.10.006 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1396.xml |
| 035 | |a (DE-627)NLM363760709 | ||
| 035 | |a (NLM)37883979 | ||
| 035 | |a (PII)S0002-9297(23)00359-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Linder, Jodell E |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Prospective, multi-site study of healthcare utilization after actionable monogenic findings from clinical sequencing |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.11.2023 | ||
| 500 | |a Date Revised 03.05.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 American Society of Human Genetics. All rights reserved. | ||
| 520 | |a As large-scale genomic screening becomes increasingly prevalent, understanding the influence of actionable results on healthcare utilization is key to estimating the potential long-term clinical impact. The eMERGE network sequenced individuals for actionable genes in multiple genetic conditions and returned results to individuals, providers, and the electronic health record. Differences in recommended health services (laboratory, imaging, and procedural testing) delivered within 12 months of return were compared among individuals with pathogenic or likely pathogenic (P/LP) findings to matched individuals with negative findings before and after return of results. Of 16,218 adults, 477 unselected individuals were found to have a monogenic risk for arrhythmia (n = 95), breast cancer (n = 96), cardiomyopathy (n = 95), colorectal cancer (n = 105), or familial hypercholesterolemia (n = 86). Individuals with P/LP results more frequently received services after return (43.8%) compared to before return (25.6%) of results and compared to individuals with negative findings (24.9%; p < 0.0001). The annual cost of qualifying healthcare services increased from an average of $162 before return to $343 after return of results among the P/LP group (p < 0.0001); differences in the negative group were non-significant. The mean difference-in-differences was $149 (p < 0.0001), which describes the increased cost within the P/LP group corrected for cost changes in the negative group. When stratified by individual conditions, significant cost differences were observed for arrhythmia, breast cancer, and cardiomyopathy. In conclusion, less than half of individuals received billed health services after monogenic return, which modestly increased healthcare costs for payors in the year following return | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a actionable genetic findings | |
| 650 | 4 | |a clinical outcomes | |
| 650 | 4 | |a electronic health records | |
| 650 | 4 | |a healthcare costs | |
| 650 | 4 | |a healthcare utilization | |
| 650 | 4 | |a monogenic sequencing | |
| 650 | 4 | |a return of results | |
| 650 | 4 | |a translational | |
| 700 | 1 | |a Tao, Ran |e verfasserin |4 aut | |
| 700 | 1 | |a Chung, Wendy K |e verfasserin |4 aut | |
| 700 | 1 | |a Kiryluk, Krzysztof |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Cong |e verfasserin |4 aut | |
| 700 | 1 | |a Weng, Chunhua |e verfasserin |4 aut | |
| 700 | 1 | |a Connolly, John J |e verfasserin |4 aut | |
| 700 | 1 | |a Hakonarson, Hakon |e verfasserin |4 aut | |
| 700 | 1 | |a Harr, Margaret |e verfasserin |4 aut | |
| 700 | 1 | |a Leppig, Kathleen A |e verfasserin |4 aut | |
| 700 | 1 | |a Jarvik, Gail P |e verfasserin |4 aut | |
| 700 | 1 | |a Veenstra, David L |e verfasserin |4 aut | |
| 700 | 1 | |a Aufox, Sharon |e verfasserin |4 aut | |
| 700 | 1 | |a Chisholm, Rex L |e verfasserin |4 aut | |
| 700 | 1 | |a Gordon, Adam S |e verfasserin |4 aut | |
| 700 | 1 | |a Hoell, Christin |e verfasserin |4 aut | |
| 700 | 1 | |a Rasmussen-Torvik, Laura J |e verfasserin |4 aut | |
| 700 | 1 | |a Smith, Maureen E |e verfasserin |4 aut | |
| 700 | 1 | |a Holm, Ingrid A |e verfasserin |4 aut | |
| 700 | 1 | |a Miller, Erin M |e verfasserin |4 aut | |
| 700 | 1 | |a Prows, Cynthia A |e verfasserin |4 aut | |
| 700 | 1 | |a Elskeally, Omar |e verfasserin |4 aut | |
| 700 | 1 | |a Kullo, Iftikhar J |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Christopher |e verfasserin |4 aut | |
| 700 | 1 | |a Jose, Sheethal |e verfasserin |4 aut | |
| 700 | 1 | |a Manolio, Teri A |e verfasserin |4 aut | |
| 700 | 1 | |a Rowley, Robb |e verfasserin |4 aut | |
| 700 | 1 | |a Padi-Adjirackor, Nana Addo |e verfasserin |4 aut | |
| 700 | 1 | |a Wilmayani, Ni Ketut |e verfasserin |4 aut | |
| 700 | 1 | |a City, Brittany |e verfasserin |4 aut | |
| 700 | 1 | |a Wei, Wei-Qi |e verfasserin |4 aut | |
| 700 | 1 | |a Wiesner, Georgia L |e verfasserin |4 aut | |
| 700 | 1 | |a Rahm, Alanna Kulchak |e verfasserin |4 aut | |
| 700 | 1 | |a Williams, Janet L |e verfasserin |4 aut | |
| 700 | 1 | |a Williams, Marc S |e verfasserin |4 aut | |
| 700 | 1 | |a Peterson, Josh F |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t American journal of human genetics |d 1949 |g 110(2023), 11 vom: 02. Nov., Seite 1950-1958 |w (DE-627)NLM000025461 |x 1537-6605 |7 nnns |
| 773 | 1 | 8 | |g volume:110 |g year:2023 |g number:11 |g day:02 |g month:11 |g pages:1950-1958 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ajhg.2023.10.006 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 110 |j 2023 |e 11 |b 02 |c 11 |h 1950-1958 | ||